India Globalization Advances Pre-Clinical Studies & CAM Products — CFN Media

Seattle Washington, Feb. 26, 2018 (GLOBE NEWSWIRE) — CFN Media Group (“CFN Media”), the leading agency and financial media network dedicated to the North American cannabis industry, announces publication of an article covering India Globalization Capital Inc’s (NYSE MKT: IGC) pursuit of numerous pre-clinical studies involving cannabinoids, while developing Complementary Alternative Medicines in the near-term to help patients and drive revenue.

The cannabis industry has struggled with clinical trials due to the federal prohibition of cannabis and the difficulty in procuring cannabis plants for research. While the regulatory environment is showing signs of improvement, there are only a handful of companies that are pursuing rigorous clinical trials to prove the safety and efficacy of cannabinoids in treating underlying medical conditions. And, investors may want to take a closer look at these companies as they progress.

Importance of Clinical Trials

Clinical trials

... read more at: https://globenewswire.com/news-release/2018/02/26/1387332/0/en/India-Globalization-Advances-Pre-Clinical-Studies-CAM-Products-CFN-Media.html

by